LAKEWOOD, Colo., Aug. 9, 2012 /PRNewswire/ -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (the “Company”) today reported a 14% increase in revenue and a 25% increase in net income for the first quarter of fiscal 2013, ended June 30, 2012.
Highlights:
- First quarter revenues increased 14% compared to the same period last fiscal year
- First quarter net income increased 25% to $2,099,000 compared to the same period last fiscal year
- First quarter non-GAAP adjusted net income increased 29% to $2,482,0001
- We acquired specific assets and certain liabilities of Bios International Corporation
For the first quarter of fiscal 2013, net revenues increased 14% to $10,559,000 from $9,297,000 in the same quarter last year. GAAP net income for the quarter increased 25% to $2,099,000 or $0.59 per diluted share compared to $1,679,000 or $0.49 per diluted share one year ago.
On a non-GAAP basis (which excludes acquisition related intangible amortization, net of tax effects), adjusted net income for the first quarter ended June 30, 2012 increased 29% to $2,482,000 or $0.70 per diluted share of common stock compared to $1,918,000 or $0.56 per diluted share of common stock last year.
On May 15, 2012, we completed a business combination (the “Bios Acquisition”) by acquiring specific assets and assuming certain liabilities of Bios International Corporation, a New Jersey corporation (“Bios”). The Bios Acquisition further diversifies and grows our Instruments division, while maintaining or improving our historic profitability metrics.
“The financial results for Mesa’s first quarter represent a great start to our fiscal 2013,” said John J. Sullivan, President and Chief Executive Officer. “Our revenues increased 14% compared to this quarter last year, stemming from approximately 5% organic growth and the remainder from the addition of the Bios products. More importantly, all of our profitability metrics improved this quarter. Compared to the first quarter of last year, Gross Margins increased from 58% to 61%, Operating Income increased from 29% of sales to 30%, and Net Income increased from 18% of sales to 20%. Mesa’s increased profitability was due to a combination of improved manufacturing efficiency in our Biological Indicator operations and the newly added Bios products, which enjoy generally higher margins than any of the other product lines. The financial results for our first quarter reflect one of our primary strategies, which is to increase both revenue and net income through a combination of organic and acquisition-related growth.”
During the first quarter of fiscal 2013, sales of the Company’s Instrumentation products and services increased 18%. The revenue increase in the first quarter was primarily due to the Bios Acquisition.
During the first quarter of fiscal 2013, sales of the Company’s Biological Indicator products increased 10%, compared to the same period last fiscal year. The increase in Biological Indicator sales during the quarter was due to organic growth.
Mesa has two segments Our Instruments Division manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, and petrochemical industries. Our Biological Indicators Division manufactures and markets biological indicators and distributes chemical indicators used to assess the effectiveness of sterilization processes in the hospital, dental, medical device and pharmaceutical industries. We follow a philosophy of manufacturing a high quality product and providing a high level of on-going service for those products.
This news release contains forward-looking statements which involve risks and uncertainties. The Company’s actual results could differ materially from those in any such forward-looking statements. Additional information concerning important factors that could cause results to differ materially from those in any such forward-looking statement is contained in the Company’s Annual Report on Form 10-K for the year ended March 31, 2012 as filed with the Securities and Exchange Commission, and from time to time in the Company’s other reports on file with the Commission.
1 The non-GAAP measures of adjusted net income and adjusted earnings per share are defined to exclude the impacts of non-cash intangibles amortization, net of its tax effects. A reconciliation between these non-GAAP measures and their GAAP counterparts is set forth in the table below, along with additional information regarding their use.
